Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
Raymond T. Chung, M.D., Janet Andersen, Sc.D., Paul Volberding, M.D., Gregory K. Robbins, M.D., Tun Liu, M.S., Kenneth E. Sherman, M.D., Ph.D., Marion G. Peters, M.D., Margaret J. Koziel, M.D., Atul K. Bhan, M.D., Beverly Alston, M.D., Dodi Colquhoun, B.S., Tom Nevin, M.S., George Harb, M.D., Charles van der Horst, M.D., for the AIDS Clinical Trials Group A5071 Study Team
Background Chronic hepatitis C virus (HCV) infection is a causeof major complications in persons who are also infected withthe human immunodeficiency virus (HIV). However, the treatmentof HCV infection in such persons has been associated with ahigh rate of intolerance and a low rate of response. We conducteda multicenter, randomized trial comparing peginterferon plusribavirin with interferon plus ribavirin for the treatment ofchronic hepatitis C in persons coinfected with HIV.
Methods A total of 66 subjects were randomly assigned to receive180 µg of peginterferon alfa-2a weekly for 48 weeks, and67 subjects were assigned to receive 6 million IU of interferonalfa-2a three times weekly for 12 weeks followed by 3 millionIU three times weekly for 36 weeks. Both groups received ribavirinaccording to a dose-escalation schedule. At week 24, subjectswho did not have a virologic response (those who had an HCVRNA level greater than or equal to 60 IU per milliliter) underwentliver biopsy, and medications were continued in subjects witheither a virologic response or histologic improvement.
Results Treatment with peginterferon and ribavirin was associatedwith a significantly higher rate of sustained virologic response(an HCV RNA level of less than 60 IU per milliliter 24 weeksafter completion of therapy) than was treatment with interferonand ribavirin (27 percent vs. 12 percent, P=0.03). In the groupgiven peginterferon and ribavirin, only 14 percent of subjectswith HCV genotype 1 infection had a sustained virologic response(7 of 51), as compared with 73 percent of subjects with an HCVgenotype other than 1 (11 of 15, P<0.001). Histologic responseswere observed in 35 percent of subjects with no virologic responsewho underwent liver biopsy.
Conclusions In persons infected with HIV, the combination ofpeginterferon and ribavirin is superior to the combination ofinterferon and ribavirin in the treatment of chronic hepatitisC. These regimens may provide clinical benefit even in the absenceof virologic clearance. The marked discrepancy in the ratesof sustained virologic response between HCV genotypes indicatesthat strategies are needed to improve the outcome in personsinfected with HCV genotype 1.
Source Information
From Massachusetts General Hospital, Boston (R.T.C., G.K.R., A.K.B.); Harvard School of Public Health, Boston (J.A., T.L.); the University of California, San Francisco, San Francisco (P.V., M.G.P.); the University of Cincinnati, Cincinnati (K.E.S.); Beth Israel Deaconess Medical Center, Boston (M.J.K.); the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (B.A.); Frontier Science Technology and Research Foundation, Amherst, N.Y. (D.C.); Social and Scientific Systems, Rockville, Md. (T.N.); Roche Laboratories, Nutley, N.J. (G.H.); and the University of North Carolina, Chapel Hill (C.H.).
Address reprint requests to Dr. Chung at GRJ 825, GI Unit, Massachusetts General Hospital, Boston, MA 02114, or at rtchung{at}partners.org.
Pawlotsky, J.-M.
(2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology
2: 205-219
[Abstract]
Berenguer, J., Gonzalez-Garcia, J., Lopez-Aldeguer, J., Von-Wichmann, M. A., Quereda, C., Hernando, A., Sanz, J., Tural, C., Ortega, E., Mallolas, J., Santos, I., Miralles, P., Montes, M. L., Bellon, J. M., Esteban, H., on behalf of the GESIDA HIV/HCV cohort,
(2009). Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother
63: 1256-1263
[Abstract][Full Text]
Mira, J. A., Lopez-Cortes, L. F., Barreiro, P., Tural, C., Torres-Tortosa, M., de los Santos Gil, I., Martin-Rico, P., Rios-Villegas, M. J., Hernandez-Burruezo, J. J., Merino, D., Lopez-Ruz, M. A., Rivero, A., Munoz, L., Gonzalez-Serrano, M., Collado, A., Macias, J., Viciana, P., Soriano, V., Pineda, J. A.
(2008). Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother
62: 1365-1373
[Abstract][Full Text]
Crespo, M., Mira, J. A., Pineda, J. A., Eynde, E. V. d., Rios-Villegas, M. J., Collado, A., Giron-Gonzalez, J. A., Lopez-Cortes, L. F., Gonzalez-Serrano, M., Rivero, A., Merino, D., Esteban, J. I.
(2008). Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother
62: 793-796
[Abstract][Full Text]
Mendes-Correa, M C, Cavalheiro, N P, Mello, C, Barone, A A, Gianini, R J
(2008). Genotypic distribution of hepatitis C among hepatitis C and HIV co-infected patients in Brazil. Int J STD AIDS
19: 595-599
[Abstract][Full Text]
Aguilar Marucco, D., Gonzalez de Requena, D., Bonora, S., Tettoni, C., Bonasso, M., De Blasi, T., D'Avolio, A., Sciandra, M., Siccardi, M., Baietto, L., Trentini, L., Sinicco, A., Cariti, G., Di Perri, G.
(2008). The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother
61: 919-924
[Abstract][Full Text]
Coriat, R., Podevin, P.
(2008). Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient. Int J STD AIDS
19: 208-210
[Abstract][Full Text]
Pineda, J. A., Mira, J. A., Gil, I. d. l. S., Valera-Bestard, B., Rivero, A., Merino, D., Giron-Gonzalez, J. A., Rios-Villegas, M. J., Gonzalez-Serrano, M., Collado, A., Garcia-Garcia, J. A., Carrillo-Gomez, R., Lopez-Cortes, L. F., Gomez-Mateos, J.
(2007). Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother
60: 1347-1354
[Abstract][Full Text]
Highbarger, H. C., Hu, Z., Kottilil, S., Metcalf, J. A., Polis, M. A., Vasudevachari, M. B., Lane, H. C., Dewar, R. L.
(2007). Comparison of the Abbott 7000 and Bayer 340 Systems for Measurement of Hepatitis C Virus Load. J. Clin. Microbiol.
45: 2808-2812
[Abstract][Full Text]
Payan, C., Pivert, A., Morand, P., Fafi-Kremer, S., Carrat, F., Pol, S., Cacoub, P., Perronne, C., Lunel, F., the ANRS HC02 RIBAVIC study team,
(2007). Rapid and early virological response to chronic hepatitis C treatment with IFN {alpha}2b or PEG-IFN {alpha}2b plus ribavirin in HIV/HCV co-infected patients. Gut
56: 1111-1116
[Abstract][Full Text]
Koziel, M. J., Peters, M. G.
(2007). Viral Hepatitis in HIV Infection. NEJM
356: 1445-1454
[Full Text]
Marucco, D. A., Veronese, L., de Requena, D. G., Bonora, S., Calcagno, A., Cavecchia, I., Sinicco, A., De Rosa, F. G., Cariti, G., Di Perri, G.
(2007). Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. J Antimicrob Chemother
59: 565-568
[Abstract][Full Text]
Butt, A. A, Justice, A. C, Skanderson, M., Rigsby, M. O, Good, C. B, Kwoh, C K.
(2007). Rate and predictors of treatment prescription for hepatitis C. Gut
56: 385-389
[Abstract][Full Text]
Lin, W., Kim, S. S., Yeung, E., Kamegaya, Y., Blackard, J. T., Kim, K. A., Holtzman, M. J., Chung, R. T.
(2006). Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain.. J. Virol.
80: 9226-9235
[Abstract][Full Text]
Manns, M P, Wedemeyer, H, Cornberg, M
(2006). Treating viral hepatitis C: efficacy, side effects, and complications.. Gut
55: 1350-1359
[Full Text]
Ramanathan, S., Cheng, A., Mittan, A., Ebrahimi, R., Kearney, B. P.
(2006). Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.. J Clin Pharmacol
46: 559-566
[Abstract][Full Text]
Hughes, C. A, Shafran, S. D
(2006). Treatment of Hepatitis C in HIV-Coinfected Patients. The Annals of Pharmacotherapy
40: 479-489
[Abstract][Full Text]
Klumpp, K., Leveque, V., Le Pogam, S., Ma, H., Jiang, W.-R., Kang, H., Granycome, C., Singer, M., Laxton, C., Hang, J. Q., Sarma, K., Smith, D. B., Heindl, D., Hobbs, C. J., Merrett, J. H., Symons, J., Cammack, N., Martin, J. A., Devos, R., Najera, I.
(2006). The Novel Nucleoside Analog R1479 (4'-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture. J. Biol. Chem.
281: 3793-3799
[Abstract][Full Text]
Pivert, A., Payan, C., Morand, P., Fafi-Kremer, S., Deshayes, J., Carrat, F., Pol, S., Cacoub, P., Perronne, C., Lunel, F.
(2006). Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin. J. Clin. Microbiol.
44: 417-422
[Abstract][Full Text]
McNelis, K.
(2006). Management of Hepatitis C Infection in the HIV-Infected Patient. Journal of Pharmacy Practice
19: 37-52
[Abstract]
MAYOR, A. M., GOMEZ, M. A., FERNANDEZ, D. M., RIOS-OLIVARES, E., THOMAS, J. C., HUNTER, R. F.
(2006). MORBIDITY AND MORTALITY PROFILE OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH AND WITHOUT HEPATITIS C CO-INFECTION. Am J Trop Med Hyg
74: 239-245
[Abstract][Full Text]
Brau, N.
(2005). Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. J Antimicrob Chemother
56: 991-995
[Abstract][Full Text]
Koretz, R. L., Lipman, T. O.
(2005). Update in Gastroenterology and Hepatology. ANN INTERN MED
143: 347-354
[Full Text]
Boston, N. S., Slish, J. C.
(2005). Management of HIV Infection in Persons Co-infected With Hepatitis. Journal of Pharmacy Practice
18: 295-309
[Abstract]
Lo Re, V III, Kostman, J R
(2005). Management of chronic hepatitis C. Postgrad. Med. J.
81: 376-382
[Abstract][Full Text]
(2005). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med.
10: 3-3
[Full Text]
Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C., for the ANRS HCO2 RIBAVIC Study Team,
(2004). Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled Trial. JAMA
292: 2839-2848
[Abstract][Full Text]
Manns, M. P., Wedemeyer, H.
(2004). Treatment of Hepatitis C in HIV-Infected Patients: Significant Progress But Not the Final Step. JAMA
292: 2909-2913
[Full Text]
Taylor, L. E., Rich, J. D., Tashima, K. T., Gholam, P. M., Torriani, F. J., Dieterich, D. T., Chung, R. T., Andersen, J., Volberding, P., the AIDS Clinical Trials Group A5071 Study Team,
(2004). Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. NEJM
351: 2340-2342
[Full Text]
(2004). Rx for HCV-Coinfection: Pegylated Interferon + Ribavirin. AIDS Clin Care
2004: 1-1
[Full Text]
(2004). Pegylated Interferon Alfa-2a in Patients with HCV and HIV. JWatch Gastroenterology
2004: 5-5
[Full Text]
(2004). A Glimmer of Hope for HIV/HCV-Coinfected Patients. JWatch Infect. Diseases
2004: 3-3
[Full Text]
Previous
